Xconomy Boston’s Top 20 Stories of the Third Quarter: From A123 Expansion to Zynga Acquisition

10/1/10Follow @gthuang

The third quarter of 2010 is going out with a monsoon in New England. It seems like a good time to hole up indoors and look back at some of the top stories we’ve done at Xconomy Boston over the past three months.

These are our editors’ picks. They aren’t necessarily the ones that got the most traffic or the most attention. Rather, they are stories that highlight our unique style of on-the-scene reporting and in-depth analysis, and will stand the test of time. They range from startup profiles in health IT, security software, and drug development, to analysis pieces on leading companies’ acquisition and expansion strategies, to unique venture capital perspectives and quirky, strange-but-true facts about New England innovation leaders.

So, without further ado, here are our top 20 stories of the third quarter, in reverse chronological order (plus a bonus story, in honor of Unica founder Yuchun Lee, a former member of the MIT Blackjack Team, selling his company to IBM for $21 a share):

Genzyme Boss Henri Termeer Not Ready to Sell to Sanofi, Ride Into the Sunset, Sources Say

MeYou Health Enters Social Gaming Realm with Daily Challenge for Improving Well-Being

IBM’s Software Acquisition Strategy in Massachusetts (Plus Tips on Getting Acquired) From VP Mike Loria

Skyhook, Fighting for Its Life in Suit Against Google, Cries Foul: “Call in the Referees and Review the Tape”

Bluebird Bio, Third Rock & Genzyme’s Gene Therapy Bet, Shows Promise for Blood Disorder

Who Knew? Part 3: Xconomy Uncovers Even More Strange-But-True Facts About Boston’s Innovation Leaders

PerkinElmer Expects to Make Acquisitions After $500M Business Sale: CEO Talks Boston-Area Talent and Growth in Software, Imaging

A123 Opens Lithium Ion Battery Plant in Michigan, Wants to Create Global Hub for Electric Vehicles

Good Start Genetics Emerges from Stealth with $18M Series A Round

Reality Show Project Seeks to Capture MassChallenge Competitors in Their Entrepreneurial Element

Vertex Nails Third Big Trial With Hepatitis C Drug, In Toughest Patients to Treat

The Unica Story: Yuchun Lee’s Journey From MIT Blackjack Team to IBM Acquisition

Don’t Confuse Getting to Market with Building a Company: Charles River Ventures’ Izhar Armony Busts Some Micro-VC Myths

Taking a VC Approach to Charity: Greylock Veteran’s Alzheimer’s Research Foundation Dares to Be Great

TechStars Alum Baydin Launches Gmail Plug-In to Keep You From Forgetting to Send Important E-mails

Zynga Buys Conduit Labs; Social Gaming Giant’s Footprint Now Includes Boston

Arbor Networks Acquisition Is a Tale of Two Cities—and a Strategic Move Into Wider World of Wireless

Kendall Square Wants an Entrepreneurial Walk of Fame—and So Should Every Innovation Hub

Is Boston Becoming a Hub for Female Tech Entrepreneurs? Maybe, and Here’s Why

Greylock’s Henry McCance on Why the Firm Moved Its HQ to Silicon Valley and How Boston Must Find Its Google

Euthymics, Led by Orexigen Vet, Nabs $24M for Depression Drug With Fewer Side Effects

Gregory T. Huang is Xconomy's Deputy Editor, National IT Editor, and the Editor of Xconomy Boston. You can e-mail him at gthuang@xconomy.com or call him at 617-252-7323. Follow @gthuang

By posting a comment, you agree to our terms and conditions.